Controlled release formulations of orally-active medicaments
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/22
A61K-009/30
A61K-009/52
A61K-009/56
출원번호
US-0194453
(1980-10-17)
발명자
/ 주소
Dunn James M. (Shreveport LA) Lampard John F. (Shreveport LA)
출원인 / 주소
Boots Pharmaceuticals, Inc. (Nottingham GB2 03)
인용정보
피인용 횟수 :
42인용 특허 :
2
초록▼
An improved tablet formulation is provided comprising an effective amount of an active therapeutic agent, especially an acidic therapeutic agent such as aspirin, a release-controlling agent, and an erosion-promoting agent in relative amounts to provide a criticality factor of less than 450, and in p
An improved tablet formulation is provided comprising an effective amount of an active therapeutic agent, especially an acidic therapeutic agent such as aspirin, a release-controlling agent, and an erosion-promoting agent in relative amounts to provide a criticality factor of less than 450, and in proportions of release-controlling and erosion-promoting agent, respectively, between 0.8-1.6 and 1.0-7.5 weight percent per tablet. The tablets of this invention exhibit zero order release in vitro and closely approximate zero order absorption in vivo. The aspirin tablets of the invention produce minimal epigastric distress and can be administered twice-a-day to provide the desired therapeutic effect. The preferred release-controlling agent is cellulose acetate phthalate and the preferred erosion-promoting agent is corn starch.
대표청구항▼
A compressed, controlled-release tablet suitable for oral administration, said tablet consisting essentially of an effective amount of an orally-active therapeutic agent selected from aspirin and a nonsteroidal arylalkanoic anti-inflammatory agent, a release-controlling agent, and an erosion-promoti
A compressed, controlled-release tablet suitable for oral administration, said tablet consisting essentially of an effective amount of an orally-active therapeutic agent selected from aspirin and a nonsteroidal arylalkanoic anti-inflammatory agent, a release-controlling agent, and an erosion-promoting agent, in proportions which provide a criticality factor between 20 and 450, calculated according to the formula: CA/(1/CS)=CF wherein: CA is the milligram per tablet content of therapeutic agent divided by the milligram per tablet content of release-controlling agent, CS is the milligram per tablet content of erosion-promoting agent divided by the milligram per tablet content of release-controlling agent, and CF is the criticality factor, said proportions including 0.8 to 1.6 weight percent per tablet of said release-controlling agent and 1.0 to 7.5 weight percent per tablet of said erosion-promoting agent, wherein the release-controlling agent is selected from the group consisting of cellulose acetate phthalate, cellulose acetate derivatives, shellac, zein, acrylic resins, ethylcellulose, hydroxypropylmethylcellulose phthalate, sandarac, and modified shellac; and wherein the erosion-promoting agent is selected from the group consisting of corn starch, rice starch, potato starch and other vegetable starches, modified starch, starch derivatives, cellulose, cellulose derivatives, modified cellulose, modified cellulose derivatives, alginic acid, alginates, bentonite, veagum, cross-linked polyvinyl pyrrolidone, ion exchange resins, and gums.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (2)
Leslie Stewart Thomas (Aberdeen SC), Slow release pharmaceutical compositions.
Dunn James M. (Littleton CO) Haas Ronald T. (Highland Ranch CO), Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory co.
Frisbee Steven E. (Town of New Scotland ; Albany County NY), Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith.
Lenaerts, Vincent; Beck, Roland Herwig Friedrich; Van Bogaert, Elsie; Chouinard, Francois; Hopcke, Reiner; Desevaux, Cyril, Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture.
Streuff Bernhard (Cologne DEX) Ptter ; deceased Johann (late of Wuppertal DEX by Elisabeth Ptter ; sole heiress), Delayed-action acetylsalicylic acid formulations for oral administration.
Legrand, Valérie; Castan, Catherine; Meyrueix, Rémi; Soula, Gérard, Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles.
Castan, Catherine; Guimberteau, Florence; Meyrueix, Rémi, Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).
Castan, Catherine; Guimberteau, Florence; Meyrueix, Rémi, Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).
Radebaugh Galen W. (Chester NJ) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release pharmaceutical formulation and process.
Edward M. Rudnic ; Beth A. Burnside ; Henry H. Flanner ; Sandra E. Wassink ; Richard A. Couch ; Jill E. Pinkett, Soluble form osmotic dose delivery system.
Rudnic Edward M. ; Burnside Beth A. ; Flanner Henry H. ; Wassink Sandra E. ; Couch Richard A. ; Pinkett Jill E., Soluble form osmotic dose delivery system.
Ghebre-Sellassie Isaac (Stanhope NJ) Nesbitt ; Jr. Russell U. (Somerville NJ) Iyer Uma (Mendham NJ) Fawzi Mahdi B. (Flanders NJ), Sustained release pharmaceutical preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.